Isconova enters strategic collaboration with Jenner Institute

14/10/2010 08:50:00

Isconova has entered a global, strategic collaboration with Jenner Institute – one of the leading vaccine institutes in the world. The aim of the collaboration is to develop vaccines, including a malaria vaccine, by using Isconova’s knowledge and products.

Initially, Isconova’s adjuvant Matrix M™ will be used in development of a malaria vaccine, a clinical phase I study is planned to be initiated in 2011. Each year, 250 million people are affected by malaria, and almost one million people die from the disease annually. Today there are no malaria vaccines available on the market. Jenner Institute did a thorough evaluation of commercially available adjuvant before Matrix M™ and Isconova were selected.

”Recently, we announced a collaboration with the Swiss biotech-company Evolva that will use Matrix M™ in pre-clinical studies of substances that can offer protection in case of bio-terrorism. Now we have entered another strategic collaboration, this time with Jenner Institute – one of the global leaders in vaccine research – where Isconova’s adjuvant will be part of their project for developing a malaria vaccine. Both these collaborations represent large commercial potential and we look forward to the results of these studies”, comments Isconova’s CEO Lena Söderström.

For more information, please contact:

Lena Söderström, CEO Isconova
Phone +46 70-816 39 12, e-mail: lena.soderstrom@isconova.com

About Isconova

Isconova AB is a Swedish research and development company with a patented technology that improves the effect and duration of vaccines. Isconova develops vaccines together with partners on the veterinary and human markets and has, since 2005, production and sales of vaccine systems on the veterinary market. www.isconova.se

About Jenner Institute

Jenner Institute – one of the global leaders in vaccine research – is a partnership between the University of Oxford and the Institute for Animal Health. The Institute comprises the research activities of over 20 Jenner Investigators who head leading research groups spanning human and veterinary vaccine research and development. The goal is to develop novel, innovative vaccines against major global diseases.
www.jenner.ac.uk

About Matrix M™

Matrix M™ is Isconova’s patented adjuvant for use in vaccines for humans and some animals, antibody production and immunological research.

About adjuvans

Adjuvants are substances that improve the effect and duration of vaccines.